Prostate-Cancer Test May Reduce Repeat Biopsies: Study

A new gene-based test for prostate cancer may reduce the need to repeat painful biopsies that can also cause serious infections, according to a study to be published in the Journal of Urology.

The ConfirmMDx test, sold by MDxHealth SA (MDXH) and based on technology developed at Johns Hopkins University, examined samples from biopsies and confirmed whether a patient was clear of cancer with 90 percent accuracy, according to the study of 498 men who underwent a second biopsy within 30 months. The findings will appear in the November issue of the journal, according to the Liege, Belgium-based company.

Read the full story:

Source: Bloomberg